AZD 3199

Drug Profile

AZD 3199

Alternative Names: AZD3199

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Apr 2012 Final efficacy data from a phase II trial in COPD presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011) .
  • 31 Dec 2011 Discontinued - Phase-I for Asthma in United Kingdom (Inhalation)
  • 31 Dec 2011 Discontinued - Phase-II for Asthma in Denmark (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top